News

The West Australian – Proteomics builds global patent protection for kidney test

Having climbed the IP mountain, the focus now for Proteomics is firmly set on revenue generation, with the company suggesting an indicative test price of between US$55-$150 per patient and royalties of between 5 per cent and 15 per cent being touted by the company as industry standards for “out-licensing” its intellectual property.

Article: Proteomics builds global patent protection for kidney test

Subscribe
  • This field is for validation purposes and should be left unchanged.